Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats

Toxicology Letters

Volumn 204, Issue 2-3, 2011, Pages 134-140

  Kannen, Vinicius ^a   Marini, Tassiana ^a   Turatti, Aline ^a   Carvalho, Milene C ^a   Brandão, Marcus L ^a   Jabor, Valquiria A P ^a   Bonato, Pierina S ^a   Ferreira, Frederico R ^b   Zanette, Dalila L ^b   Silva, Wilson A ^b   Garcia, Sérgio B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute of Science and Technology in Stem Cell and Cell Therapy   (Brazil)

Author keywords

Aberrant crypt foci; Colon carcinogenesis; Cyclooxygenase 2; Fluoxetine; Proliferative process; Vascular endothelial growth factor

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CYCLOOXYGENASE 2; FLUOXETINE; MESSENGER RNA; SEROTONIN; SEROTONIN 2C RECEPTOR; VASCULOTROPIN;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENICITY; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; FEEDING; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTONIN BLOOD LEVEL; SINGLE DRUG DOSE;

ANIMALS; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; FLUOXETINE; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS; RATTUS NORVEGICUS;

EID: 79958011325     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.04.024     Document Type: Article

References (48)

1. Amireault P., Dube F. Intracellular cAMP and calcium signaling by serotonin in mouse cumulus-oocyte complexes. Mol. Pharmacol. 2005, 68:1678-1687.
2. Arends J.W., Wiggers T., Verstijnen K., Bosman F.T. The occurrence and clinicopathological significance of serotonin immunoreactive cells in large bowel carcinoma. J. Pathol. 1986, 149:97-102.
3. Arimochi H., Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur. J. Pharmacol. 2006, 541:17-23.
4. Barkla D.H., Tutton P.J. Influence of histamine and serotonin antagonists on the growth of xenografted human colorectal tumors. J. Natl. Cancer Inst. 1981, 67:1207-1211.
5. Bertrand P.P., Barajas-Espinosa A., Neshat S., Bertrand R.L., Lomax A.E. Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G446-G455.
6. Bertrand P.P., Hu X., Mach J., Bertrand R.L. Serotonin (5-HT) release and uptake measured by real-time electrochemical techniques in the rat ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G1228-G1236.
7. Borges K.B.O.L., Pupo M.T., Bonato P.S. Enantioselective analysis of fluoxetine and norfluoxetine by LC in culture medium for application in biotransformation studies employing fungi. Chromatographia 2009, 70:1335-1342.
8. Briddon S.J., Leslie R.A., Elliott J.M. Comparative desensitization of the human 5-HT2A and 5-HT2C receptors expressed in the human neuroblastoma cell line SH-SY5Y. Br. J. Pharmacol. 1998, 125:727-734.
9. Brink C.B., Viljoen S.L., de Kock S.E., Stein D.J., Harvey B.H. Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells. Metab. Brain Dis. 2004, 19:51-70.
10. Choi J.S., Choi B.H., Ahn H.S., Kim M.J., Rhie D.J., Yoon S.H., Min D.S., Jo Y.H., Kim M.S., Sung K.W., Hahn S.J. Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells. Biochem. Pharmacol. 2003, 66:2125-2132.
11. Eisensamer B., Rammes G., Gimpl G., Shapa M., Ferrari U., Hapfelmeier G., Bondy B., Parsons C., Gilling K., Zieglgansberger W., Holsboer F., Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol. Psychiatry 2003, 8:994-1007.
12. El-Salhy M., Sitohy B. Triple therapy with octreotide, galanin and serotonin induces necrosis and increases apoptosis of a rat colon carcinoma. Regul. Pept. 2002, 108:55-62.
13. El-Salhy M., Sitohy B., Norrgard O. Triple therapy with octreotide, galanin, and serotonin reduces the size and blood vessel density and increases apoptosis of a rat colon carcinoma. Regul. Pept. 2003, 111:145-152.
14. Frick L.R., Palumbo M.L., Zappia M.P., Brocco M.A., Cremaschi G.A., Genaro A.M. Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem. Pharmacol. 2008, 75:1817-1826.
15. Froberg G.K., Lindberg R., Ritter M., Nordlind K. Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours. J. Comp. Pathol. 2009, 141:89-97.
16. Garcia S.B., Barros L.T., Turatti A., Martinello F., Modiano P., Ribeiro-Silva A., Vespucio M.V., Uyemura S.A. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006, 240:221-224.
17. Garcia S.B., Park H.S., Novelli M., Wright N.A. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J. Pathol. 1999, 187:61-81.
18. Gill R.K., Pant N., Saksena S., Singla A., Nazir T.M., Vohwinkel L., Turner J.R., Goldstein J., Alrefai W.A., Dudeja P.K. Function, expression, and characterization of the serotonin transporter in the native human intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G254-G262.
19. Huhnt W., Lubbe A.S. Venules and arterioles in xenotransplanted human colon adenocarcinoma critically constrict with hyperthermia and serotonin. J. Cancer Res. Clin. Oncol. 1995, 121:267-274.
20. Jin Y., Lim C.M., Kim S.W., Park J.Y., Seo J.S., Han P.L., Yoon S.H., Lee J.K. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res. 2009, 1281:108-116.
21. Kannen V., Marini T., Zanette D.L., Frajacomo F.T., Silva G.E., Silva W.A., Garcia S.B. The melatonin action on stromal stem cells within pericryptal area in colon cancer model under constant light. Biochem. Biophys. Res. Commun. 2011, 405:593-598.
22. Kubera M., Grygier B., Arteta B., Urbanska K., Basta-Kaim A., Budziszewska B., Leskiewicz M., Kolaczkowska E., Maes M., Szczepanik M., Majewska M., Lason W. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol. Rep. 2009, 61:1113-1126.
23. Lee C.S., Kim Y.J., Jang E.R., Kim W., Myung S.C. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin. Pharmacol. Toxicol. 2010, 106:446-453.
24. Lefebvre M., Marchand M., Horowitz J.M., Torres G. Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry. Life Sci. 1999, 64:805-811.
25. Liang J.T., Huang K.C., Jeng Y.M., Lee P.H., Lai H.S., Hsu H.C. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br. J. Surg. 2004, 91:355-361.
26. Lubbe A.S., Huhnt W. Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin. Int. J. Microcirc. Clin. Exp. 1994, 14:218-225.
27. Mackowiak M., Chocyk A., Sanak M., Czyrak A., Fijal K., Wedzony K. DOI, an agonist of 5-HT2A/2C serotonin receptor, alters the expression of cyclooxygenase-2 in the rat parietal cortex. J. Physiol. Pharmacol. 2002, 53:395-407.
28. Mastrangelo L., Cassidy A., Mulholland F., Wang W., Bao Y. Serotonin receptors, novel targets of sulforaphane identified by proteomic analysis in Caco-2 cells. Cancer Res. 2008, 68:5487-5491.
29. Moreira C.M., Masson S., Carvalho M.C., Brandao M.L. Exploratory behaviour of rats in the elevated plus-maze is differentially sensitive to inactivation of the basolateral and central amygdaloid nuclei. Brain Res. Bull. 2007, 71:466-474.
30. Park S.W., Kim H.S., Choi M.S., Jeong W.J., Heo D.S., Kim K.H., Sung M.W. The effects of the stromal cell-derived cyclooxygenase-2 metabolite PGE2 on proliferation of colon cancer cells. J. Pharmacol. Exp. Ther. 2011, 336:516-523.
31. Pinsky P.F., Fleshman J., Mutch M., Rall C., Charabaty A., Seligson D., Dry S., Umar A., Schoen R.E. One year recurrence of aberrant crypt foci. Cancer Prev. Res. (Phila) 2010, 3:839-843.
32. Roman A., Rogoz Z., Kubera M., Nawrat D., Nalepa I. Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacol. Rep. 2009, 61:1069-1077.
33. Serafeim A., Holder M.J., Grafton G., Chamba A., Drayson M.T., Luong Q.T., Bunce C.M., Gregory C.D., Barnes N.M., Gordon J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 2003, 101:3212-3219.
34. Skinner S.A., Frydman G.M., O'Brien P.E. Microvascular structure of benign and malignant tumors of the colon in humans. Dig. Dis. Sci. 1995, 40:373-384.
35. Skinner S.A., Tutton P.J., O'Brien P.E. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 1990, 50:2411-2417.
36. Stepulak A., Rzeski W., Sifringer M., Brocke K., Gratopp A., Kupisz K., Turski L., Ikonomidou C. Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol. Ther. 2008, 7:1685-1693.
37. Sulaiman P., Joseph B., Kaimal S.B., Paulose C.S. Decreased hepatic 5-HT1A receptors during liver regeneration and neoplasia in rats. Neurochem. Res. 2008, 33:444-449.
38. Todaro M., Francipane M.G., Medema J.P., Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
39. Tutton P.J., Barkla D.H. Neural control of colonic cell proliferation. Cancer 1980, 45:1172-1177.
40. Tutton P.J., Barkla D.H. Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. Br. J. Cancer 1982, 46:260-265.
41. Tutton P.J., Barkla D.H. Serotonin receptors influencing cell proliferation in the jejunal crypt epithelium and in colonic adenocarcinomas. Anticancer Res. 1986, 6:1123-1126.
42. Tutton P.J., Barkla D.H. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells (review). Anticancer Res. 1987, 7:1-12.
43. Tutton P.J., Steel G.G. Influence of biogenic amines on the growth of xenografted human colorectal carcinomas. Br. J. Cancer 1979, 40:743-749.
44. Valcz G., Krenacs T., Sipos F., Leiszter K., Toth K., Balogh Z., Csizmadia A., Muzes G., Molnar B., Tulassay Z. The role of the bone marrow derived mesenchymal stem cells in colonic epithelial regeneration. Pathol. Oncol. Res. 2011, 17:11-16.
45. Waldner M.J., Wirtz S., Jefremow A., Warntjen M., Neufert C., Atreya R., Becker C., Weigmann B., Vieth M., Rose-John S., Neurath M.F. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J. Exp. Med. 2010, 207:2855-2868.
46. Wang L., Chen W., Xie X., He Y., Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp. Oncol. 2008, 30:42-51.
47. Wong W.M., Garcia S.B., Wright N.A. Origins and morphogenesis of colorectal neoplasms. APMIS 1999, 107:535-544.
48. Wong W.M., Mandir N., Goodlad R.A., Wong B.C., Garcia S.B., Lam S.K., Wright N.A. Histogenesis of human colorectal adenomas and hyperplastic polyps: the role of cell proliferation and crypt fission. Gut 2002, 50:212-217.